United Therapeutics Corp 
Welcome,         Profile    Billing    Logout  
 10 Products   74 Diseases   10 Products   36 Trials   2505 News 


12345678910111213...2728»
  • ||||||||||  Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
    Perioperative Optimization for Tonsillectomy and Adenoidectomy in Pediatric Patient with Severe Pulmonary Hypertension and Moderate Obstructive Sleep Apnea (Monitor 15; Exhibit Hall, Street Level) -  Jul 12, 2025 - Abstract #ASA2025ASA_2472;    
    Patient's pulmonary hypertension and right heart failure was managed with a reverse Potts shunt, continuous subcutaneous treprostinil, oral ambrisentan, oral sildenafil, and oral digoxin. Perioperative optimization of this patient required continuation of pulmonary anti-hypertensives, adequate premedication to facilitate controlled intravenous induction, and postoperative sedation to minimize the risk of worsening right heart function during emergence from general anesthesia.
  • ||||||||||  treprostinil / Generic mfg., Tyvaso (treprostinil) / United Therapeutics Corp
    Review, Journal:  Practical Considerations for Managing Patients on Tyvaso DPI (Treprostinil Inhalation Powder). (Pubmed Central) -  Jul 4, 2025   
    This review provides an overview of inhaled prostacyclin therapy with a focus on practical considerations for managing PAH and PH-ILD patients treated with Tyvaso DPI. Recommendations from a panel of pulmonary hypertension advanced practice providers include patient selection, education, communication, onboarding and monitoring, transition and titration, side effect mitigation, and the availability of clinician- and patient-facing resources.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
    Trial completion date, Trial primary completion date:  SAPPHIRE: Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (clinicaltrials.gov) -  Jun 30, 2025   
    P2,  N=10, Recruiting, 
    Recommendations from a panel of pulmonary hypertension advanced practice providers include patient selection, education, communication, onboarding and monitoring, transition and titration, side effect mitigation, and the availability of clinician- and patient-facing resources. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jan 2025 --> Dec 2025
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis, Omblastys (131I-omburtamab) - Y / mAbs Therap
    Review, Journal:  From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology. (Pubmed Central) -  Jun 26, 2025   
    Antibody-based radiotracers like 131I-omburtamab, targeting B7-H3, are emerging as promising tools for addressing difficult-to-treat tumors such as diffuse midline glioma. Collectively, these advances provide new hope for children afflicted by these devastating malignancies, offering promising solutions for more specific and precise diagnosis and, additionally, for more effective, personalized, and less toxic tumor therapies.
  • ||||||||||  P1 data, Journal:  Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab  (Pubmed Central) -  Jun 24, 2025   
    MIBG combined with dinutuximab was well tolerated with encouraging antitumor activity. Vorinostat added to this combination may augment responses in this heavily pretreated patient population.
  • ||||||||||  Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Journal:  Ocular Toxicity in GD-2 Antibody Therapy: A Case Study. (Pubmed Central) -  Jun 13, 2025   
    Measuring a change in visual acuity and pupillary response is impossible without a baseline screening before commencing GD-2 antibody therapy. Although there is significant literature and reports on the identification and management of common side effects of GD-2 antibody therapy, less common ocular toxicities are possibly underreported with little guidance on management, thus making recognition and subsequent treatment challenging for nurses and providers.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
    Journal:  Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. (Pubmed Central) -  Jun 12, 2025   
    Although there is significant literature and reports on the identification and management of common side effects of GD-2 antibody therapy, less common ocular toxicities are possibly underreported with little guidance on management, thus making recognition and subsequent treatment challenging for nurses and providers. This post hoc analysis suggests that patients with PAH and cardiovascular comorbidities can benefit from combination therapy with inhaled or oral treprostinil.
  • ||||||||||  ralinepag (APD811) / United Therapeutics Corp, Uptravi (selexipag) / J&J
    PK/PD data, Journal:  Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist. (Pubmed Central) -  Jun 9, 2025   
    This post hoc analysis suggests that patients with PAH and cardiovascular comorbidities can benefit from combination therapy with inhaled or oral treprostinil. One received a single dose of ralinepag IR (30
  • ||||||||||  Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Trial completion date, Trial primary completion date:  STING: NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (clinicaltrials.gov) -  May 13, 2025   
    P1/2,  N=31, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Trial completion:  MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) -  Apr 15, 2025   
    P1,  N=45, Completed, 
    Rates of CR+PR in this trial were similar to those previously reported. Active, not recruiting --> Completed
  • ||||||||||  ralinepag (APD811) / United Therapeutics Corp
    Trial completion date, Trial primary completion date:  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension (clinicaltrials.gov) -  Apr 3, 2025   
    P3,  N=1000, Enrolling by invitation, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Apr 2026 Trial completion date: Sep 2024 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Dec 2026
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Clinical, Journal:  Inhaled Aviptadil is a New Hope for Recovery of Lung Damage due to COVID-19. (Pubmed Central) -  Mar 25, 2025   
    Abstract is embargoed at this time. Study shows that inhaled aviptadil is well tolerated and can be used as a supplementary intervention to fasten the recovery of respiratory manifestations in hospitalized patients for COVID-19 pneumonia.
  • ||||||||||  humanised dinutuximab (Hu14.18K322A) / Essential Pharma
    Trial completion date:  Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) -  Mar 10, 2025   
    P2,  N=153, Active, not recruiting, 
    Trial completion date: Mar 2025 --> Mar 2026 Trial completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Yutrepia (treprostinil inhaled dry powder) / Liquidia Technologies
    Transitioning From Parenteral Treprostinil to LIQ861 in a Patient With PAH (Area L, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1464) -  Feb 24, 2025 - Abstract #ATS2025ATS_5965;    
    Inhaled Treprostinil therapy can offer comparable efficacy to parenteral routes in the management of PAH, while reducing systemic side effects and eliminating the need for subcutaneous or intravenous access. To our knowledge, this is the first case report of transitioning between LIQ861 and I.V. Treprostinil.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp, Yutrepia (treprostinil inhaled dry powder) / Liquidia Technologies
    The Minimal Important Difference in NT-proBNP in Various Forms of Pulmonary Hypertension (Room 301-302 (South Building, Level 3), Moscone Center; Poster Board # 410) -  Feb 24, 2025 - Abstract #ATS2025ATS_3269;    
    The estimated MID for NT-proBNP change in PAH and PH-ILD is remarkably similar -36% and -38%, respectively. Failure to achieve the MID for NT-proBNP change is strongly associated with clinically important outcomes in both PAH and PH-ILD, demonstrating that measuring NT-proBNP change over 12-16 weeks can be informative for prognosis and may be useful for decisions regarding treatment escalation in both PAH and PH-ILD.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
    TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis: Preliminary Baseline Demographics (Area M, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1623) -  Feb 24, 2025 - Abstract #ATS2025ATS_2007;    
    P3
    Background use of pirfenidone or nintedanib is allowed... The prospectively designed TETON-PPF Phase 3 clinical trial is being performed in parallel with the TETON studies for IPF to avoid any delay in this potential treatment option becoming available for PPF patients, who currently have limited treatment options but a similar prognosis as IPF patients.
  • ||||||||||  Trevyent (treprostinil PatchPump) / Correvio, United Therapeutics Corp
    Patient Reported Experience of Participants in the ARTISAN Study for Pulmonary Arterial Hypertension (PAH) (Area C, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P256) -  Feb 24, 2025 - Abstract #ATS2025ATS_1650;    
    Of these, 41%(7/17) respondents expressed some concerns prior to participation in the study, while the majority (88%; 15/17) stated that pre-teaching and home health visits with a nurse before participation better prepared them and ameliorated their concerns for participation in the study. For questions related to concerns during participation, 71% (12/17) responded that they were able to manage everyday tasks, while the remaining 29% had various levels of difficulty.
  • ||||||||||  Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, treprostinil / Generic mfg., Uptravi (selexipag) / J&J
    Journal:  Transition from parenteral treprostinil to selexipag aiming at hemodynamic targets in pulmonary arterial hypertension. (Pubmed Central) -  Feb 13, 2025   
    40 mmHg by receiving intensive parenteral treprostinil therapy with significant improvements in 6MWD and NT-proBNP levels, and successfully transitioned to oral selexipag. We proposed that transition strategies from parenteral treprostinil to selexipag aiming at hemodynamic targets.
  • ||||||||||  ralinepag (APD811) / United Therapeutics Corp
    Trial completion date, Trial primary completion date:  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (clinicaltrials.gov) -  Feb 4, 2025   
    P3,  N=1000, Recruiting, 
    Multidisciplinary therapy even with omission of dinutuximab in our cohort had acceptable outcomes. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells) / Northern Therap, MaxCyte, United Therapeutics Corp
    Enrollment change, Trial termination:  SAPPHIRE: Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension (clinicaltrials.gov) -  Jan 31, 2025   
    P2/3,  N=22, Terminated, 
    Enrolling by invitation --> Completed N=12 --> 22 | Active, not recruiting --> Terminated; Lower than anticipated enrollment
  • ||||||||||  Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, VentaProst (epoprostenol inhalation) / Aerogen Pharma
    TUMORAL PULMONARY HYPERTENSION SECONDARY TO GI MALIGNANCY - Rachel Wester (Board no. 262; South Hall) -  Jan 27, 2025 - Abstract #ACC2025ACC_4931;    
    Histopathological diagnosis with tissue sampling is the gold standard. The optimal management of PTTM is unclear but prior case reports discuss supportive care, chemotherapy, steroids, oxygen and PAH medications.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp, treprostinil inhaled dry powder (LIQ861) / Liquidia Technologies
    Safety of Low-Dose Oral Treprostinil in PH-HFpEF Supports Use in Patients with PAH with Cardiovascular Comorbidities (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1343;    
    P3
    Recent analyses of the FREEDOM-EV and TRIUMPH trials demonstrated no difference in treatment response or tolerability of oral and inhaled treprostinil (TRE) with increasing CV comorbidity burden...No oral TRE patients died during the study; one (2%) PBO patient died during the study.Conclusion In SOUTHPAW, AEs were consistent with prior TRE studies, and there were no concerning safety signals with low doses of oral TRE (study maximum dose 4 mg TID). This suggests that oral TRE may be safely used in PAH patients with CV comorbidities and risk factors for HFpEF.
  • ||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp, Rituxan (rituximab) / Roche
    Heart Lung Transplantation for Fibrosing Mediastinitis (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1273;    
    Glucocorticoids & antifungals are not beneficial. Heart lung transplantation was successful in our case and may be considered.
  • ||||||||||  ralinepag (APD811) / United Therapeutics Corp
    Developing Models for New Drugs in PAH: A Pharmacokinetic Simulation of Ralinepag (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_619;    
    P3
    The model also accurately predicted blood plasma concentrations consistent with those observed in the phase 2 study with patients with PAH.Conclusion The accuracy of this model across multiple doses and formulations suggests that it will be applicable in analyzing results from the ongoing phase 3 ADVANCE OUTCOMES study. Beyond simulating PK, we plan to extend the model to link with variables such as hemodynamics and exercise capacity, with potential utility to calculate dosing equivalencies for transition from other PAH therapies to ralinepag.